Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Research & Development (2022 - 2025)

Entrada Therapeutics has reported Research & Development over the past 4 years, most recently at $34.0 million for Q4 2025.

  • Quarterly results put Research & Development at $34.0 million for Q4 2025, up 1.65% from a year ago — trailing twelve months through Dec 2025 was $142.3 million (up 13.54% YoY), and the annual figure for FY2025 was $142.3 million, up 13.54%.
  • Research & Development for Q4 2025 was $34.0 million at Entrada Therapeutics, down from $38.4 million in the prior quarter.
  • Over the last five years, Research & Development for TRDA hit a ceiling of $38.4 million in Q3 2025 and a floor of $15.7 million in Q4 2022.
  • Median Research & Development over the past 4 years was $28.4 million (2023), compared with a mean of $27.1 million.
  • Biggest five-year swings in Research & Development: surged 80.37% in 2023 and later increased 1.65% in 2025.
  • Entrada Therapeutics' Research & Development stood at $15.7 million in 2022, then surged by 80.37% to $28.3 million in 2023, then increased by 18.08% to $33.4 million in 2024, then grew by 1.65% to $34.0 million in 2025.
  • The last three reported values for Research & Development were $34.0 million (Q4 2025), $38.4 million (Q3 2025), and $37.9 million (Q2 2025) per Business Quant data.